EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Gossamer Bio's Enterprise Value is $66.73 Mil.
Gossamer Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-159.19 Mil. Therefore, Gossamer Bio's EV-to-FCF for today is -0.42.
The historical rank and industry rank for Gossamer Bio's EV-to-FCF or its related term are showing as below:
GOSS'
s EV-to-FCF Range Over the Past 10 Years
Min: -4.13 Med: 0 Max: 0
Current: -0.42
GOSS's EV-to-FCF is ranked worse than 100% of 394
companies
in the Biotechnology industry
Industry Median: 4.23
vs GOSS: -0.42
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Gossamer Bio's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Gossamer Bio's EV-to-FCF
For the Biotechnology subindustry, Gossamer Bio's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gossamer Bio's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gossamer Bio's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Gossamer Bio's EV-to-FCF falls into.
Gossamer Bio EV-to-FCF Calculation
Gossamer Bio's EV-to-FCF for today is calculated as:
Gossamer Bio's current Enterprise Value is $66.73 Mil.
Gossamer Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-159.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gossamer Bio (NAS:GOSS) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Gossamer Bio's PE Ratio for today is calculated as:
Gossamer Bio's share price for today is $0.668.
Gossamer Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.330.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Gossamer Bio EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Gossamer Bio's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GOSS has been successfully added to your 